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Cox-2 = cyclo-oxygenase-2; EMEA = European Medicines Agency; NSAID = non-steroidal anti-inflammatory drug; OA = osteoarthritis; RA =
rheumatoid arthritis.
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Abstract
Reviews of oral opioid trials have shown that many side-effects
need to be considered when treating patients with non-operable
osteoarthritis and soft-tissue problems. European and American
guidelines recommend their use with or without paracetamol. The
controversy surrounding the use of non-steroidal anti-inflammatory
drugs/cyclo-oxygenase-2 inhibitors is limiting physician and patient
choices. There is a great need for alternative medication or ways of
using current compounds.
Moore and McQuay [1], in this issue of Arthritis Research &
Therapy, reviewed 34 trials using oral opioids against
placebo or a comparator. The review included 5,500
patients; importantly, 4,000 patients contributed to the side-
effect profile. It is this profile that is significant in today’s
world of public and patient safety. Doctors and patients do
need help, and preferably evidence, to make choices when
treating all types of musculoskeletal conditions. Moore’s
review highlights two problems: first, that the trials were of
short duration, and second, that the side-effect profiles were
a problem, causing patient withdrawals of at least 22%.
The European League Against Rheumatism recommends
opioid analgesics with or without paracetamol as useful
alternatives for patients in whom non-steroidal anti-
inflammatory drugs (NSAIDs), including cyclo-oxygenase-2
(Cox-2) selective inhibitors, are contra-indicated, ineffective
and/or poorly tolerated [2,3].
The American Pain Society and the American College of
Rheumatology give similar advice for the use of opioids in
rheumatoid arthritis (RA) as well as osteoarthritis (OA) [4,5].
Trials have shown that opioids are effective in OA and RA
and improve sleep and quality of life [6]. If opioids are
effective, are they safe? Schug and colleagues [7] showed
that they have a good safety record and most have a high
therapeutic index. In acute overdose, respiratory failure can
occur but there does not seem to be any specific organ
toxicity. The side-effects of nausea, vomiting, somnolence
and sedation can present problems. It is accepted that
patients usually rapidly develop tolerance to these side-
effects. Unfortunately, tolerance does not develop for
constipation, so this side-effect needs treatment. In Moore’s
review, dry mouth was experienced by 25% of patients,
which is a significant problem for this age group of 55 years
and over. These problems do limit the use of oral opioids –
most patients who require medication for non-cancer pains
are over 65 years old and very often constipation is already a
problem, especially with the use of concomitant medication
for co-morbidities. Constipation as a drug side-effect is
rarely acceptable to patients, even in the older age groups,
as most people wish to enjoy independence and the best
possible quality of life. The withdrawal rate in trials is 22%
[1], but this is likely to be an underestimation; in reality, most
patients cannot tolerate nausea and somnolence for long
even if they are assured that it will wear off given time. Car
driving becomes difficult, even dangerous, and the quality of
life generally deteriorates.
It is important, when using opioids, to select patients with
care. All patients require a physical, psychological and social
assessment. This will include addressing patients’ beliefs,
fears and expectations about their pain and the use of
opioids. Care in opioid use must be exercised if there is or
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has been a history of drug or alcohol use or psychiatric
problems such as depression, psychosis or any risk or history
of suicidal tendencies. This assessment should also take into
account similar factors relevant to any household member(s).
The emotive problems of dependence and addiction need
addressing. When treating pain, addiction is defined as ‘a
persistent pattern of dysfunctional opioid use that may involve
any or all of the following: adverse consequences associated
with the use of opioids; loss of control over the use of
opioids, preoccupation with obtaining opioids, despite the
presence of adequate analgesia’ [8,9].
Physical dependence is a physiological phenomenon
characterized by symptoms associated with abrupt
termination of regular opioid use [8,9]; it is not predictive nor
diagnostic of addiction. The withdrawal effects of insomnia,
muscle contraction and nausea are usually non-serious and
generally last from 7 to 10 days [7]; these can be minimised
by a gradual tapering of therapy.
I think it is the fear, by both patients and doctors, of addiction
and dependence that has limited the use of oral opioids. This
problem continues to create prejudice against the liberal use
of opioid drugs in conditions other than their use for cancer
pain. It is unlikely that Moore’s review of oral opioids [1], the
removal of some Cox-2 inhibitors or the growing evidence
that NSAIDs are probably just as toxic as Cox-2 inhibitors to
the cardiovascular system will overcome this reluctance to
prescribe opioids to vast numbers of patients.
If a proper initial assessment of patients and their social
circumstances is undertaken, then fears can be allayed and
patients ‘at risk’ can be excluded from opioid treatment.
Regular follow-up assessments should pre-empt most
problems. Opioid drugs significantly reduce pain scores for
patients with chronic non-malignant pain and, importantly,
clinical trials also show that they improve a patient’s quality of
life. The recent controversy around Cox-2 inhibitors/NSAIDs
has made the management of OA pain more difficult and led
to patients suffering. Assessments of patients for opioids and
wise use will begin to reverse this trend.
Many patients with soft-tissue problems and non-operable
osteoarthritis will require pain relief. Education of patients and
the use of paracetamol, glucosamine, topical NSAIDs and
rubefacients will help many but not all patients: there will be
some who require or demand more pain relief. Primary care
appointments are much longer than previously, but
appointments are still at a premium so the individualization of
treatment of all patients is still an unattainable goal. The major
drawback of the Cox-2 inhibitors/NSAID controversy is that
we are unable to treat our patients’ pain adequately; this will
continue to be true while the risks of treatment continue to
take preference over the benefits of treatment and informed
choice.
Conclusion
Patients still require pain relief; all NSAIDs/Cox-2 inhibitors
have cardiovascular and renal side-effects, and the older
NSAIDs have severe gastrointestinal ones too. Most patients
with OA requiring pain relief are over 65 years old with co-
morbidities: NSAIDs/Cox-2 inhibitors are not the preferred
choice of the European Medicines Agency (EMEA) [10]. Oral
opioids will be accepted by some patients but not the
majority. The addition of opioid matrix patches are a welcome
addition and hold out the possibility of a lower incidence of
side-effects. Matrix patches seem to be acceptable to both
patients and doctors and are less likely to be open to abuse.
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